CAS
TGTX icon

Coppell Advisory Solutions’s TG Therapeutics TGTX Stock Holding History

Coppell Advisory Solutions’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-632
Closed -$19.9K – 1703
2024
Q4 		$19.9K Hold
632
– – ﹤0.01% 889
2024
Q3 		$10.6K Hold
632
– – ﹤0.01% 1063
2024
Q2 		$10.6K Buy
+632
New +$10.1K ﹤0.01% 985
2023
Q4 		$6.75K Buy
+632
New +$7.34K ﹤0.01% 1038
2023
Q3 		– Sell
-1,901
Closed -$45.8K – 1529
2023
Q2 		$45.8K Buy
+1,901
New +$49.1K 0.01% 402

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coppell Advisory Solutions's TGTX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of TG Therapeutics (TGTX) in Q1 2025, closing a stake of 632 shares — an estimated $19.9K sold.

Coppell Advisory Solutions first reported a position in TGTX in Q2 2023 and held it in 5 quarters. The position peaked at $45.8K in Q2 2023. 376 funds tracked by Wall St. Rank hold TGTX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining TG Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 632 TG Therapeutics shares in Q1 2025, an estimated $19.9K.
  • Coppell Advisory Solutions first reported a position in TG Therapeutics in Q2 2023 and held it in 5 quarters.
  • Coppell Advisory Solutions's TG Therapeutics position peaked at $45.8K in Q2 2023.
  • 376 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.